GILD SEC Filings

Gilead Sciences, Inc. (GILD) has filed an 8-K report on February 10, 2026, announcing its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily serves to disseminate this earnings information to investors. Investors should refer to Exhibit 99.1, the press release, for detailed financial performance, including both GAAP and non-GAAP measures. Management emphasizes that while non-GAAP information is provided for enhanced operational and financial planning insights, it is not a substitute for GAAP figures. A reconciliation of these non-GAAP measures to their GAAP equivalents is available within the press release. The filing itself is procedural, directing stakeholders to the comprehensive earnings announcement for substantive financial details and commentary.

Gilead Sciences, Inc. (GILD) has filed an 8-K report disclosing a significant executive change. Effective December 5, 2025, Deborah H. Telman will step down from her role as Executive Vice President, Corporate Affairs and General Counsel. Her employment with the company is expected to conclude later in December. This transition marks the departure of a key member of Gilead's senior leadership. Investors should monitor any subsequent announcements regarding the replacement for Ms. Telman and the strategic implications of this change on corporate affairs and legal matters. The filing itself does not provide reasons for her departure or details about her future plans.

Gilead Sciences, Inc. reported solid financial results for the third quarter and first nine months of 2025, demonstrating revenue growth and a significant turnaround in profitability compared to the prior year. Total revenues for the third quarter of 2025 increased by 3% year-over-year to $7.8 billion, driven by strong performance in the HIV and Liver Disease segments, alongside a notable surge in royalty, contract, and other revenues. For the first nine months, total revenues grew 2% to $21.5 billion. The company achieved substantial net income of $3.1 billion for the quarter and $6.3 billion for the nine-month period, a significant improvement from the net loss reported in the comparable periods of 2024. This profitability boost was largely attributed to the absence of substantial impairment charges seen in the prior year, coupled with increased royalty income and lower acquired R&D expenses. Diluted earnings per share also saw a strong recovery, reflecting these improved financial outcomes.

Gilead Sciences, Inc. (GILD) has filed an 8-K report on October 30, 2025, announcing its financial results for the quarter ended September 30, 2025. The report primarily directs investors to a press release (Exhibit 99.1) for detailed financial outcomes. Investors should review this press release to understand the company's performance in the most recent fiscal quarter. The company emphasizes the presentation of both GAAP and non-GAAP financial measures. Management considers the non-GAAP figures valuable for a deeper understanding of operational performance, as they are used for internal strategic planning. A crucial element for investors is the reconciliation provided within the press release, which bridges the differences between GAAP and non-GAAP reporting, allowing for a comprehensive financial assessment.

Gilead Sciences, Inc. (GILD) announced on October 6, 2025, that it has reached settlement agreements with Lupin Ltd., Cipla Ltd., and Laurus Labs Ltd. These agreements resolve patent litigations concerning generic versions of Biktarvy®. The key outcome for investors is that these settlements prevent generic entry of Biktarvy® in the United States until at least April 1, 2036. This extended patent protection for Biktarvy®, a significant product for Gilead, provides considerable revenue certainty for the coming years. While the filing includes standard forward-looking statements and disclaimers regarding potential risks and uncertainties, the primary takeaway is the extended market exclusivity for a key revenue driver, which should be viewed positively by investors.

Gilead Sciences, Inc. (GILD) announced a key leadership change in its financial reporting structure through an 8-K filing on August 13, 2025. The company has appointed Erin Burkhart as the new Senior Vice President, Controllership and principal accounting officer, effective September 22, 2025. This appointment brings a seasoned financial executive with extensive experience in the biotechnology and pharmaceutical sectors to a critical role within Gilead's finance organization. Ms. Burkhart's prior roles include Group Vice President and Chief Accounting Officer at BioMarin Pharmaceutical Inc., and various senior accounting and finance positions at Eli Lilly and Company. Her background in public accounting with major firms and her CPA certification underscore her qualifications for overseeing Gilead's financial reporting. This transition marks a change in leadership for the principal accounting officer role, with Diane E. Wilfong stepping down from her interim position.

Gilead Sciences, Inc. (GILD) announced its financial results for the quarter ended June 30, 2025, via a press release filed on August 7, 2025. This 8-K filing primarily serves to report these earnings, providing investors with an update on the company's operational and financial performance. The press release, attached as Exhibit 99.1, contains detailed financial information presented under both Generally Accepted Accounting Principles (GAAP) and non-GAAP measures. Investors should note that while Gilead presents non-GAAP financial information to offer additional insights into its performance, it is crucial to review this alongside the official GAAP financial statements. The company emphasizes that non-GAAP measures are not standardized across the industry and provides a reconciliation of these figures to GAAP in the accompanying press release. This filing acts as a notification of earnings release, directing investors to the detailed information contained within Exhibit 99.1 for a comprehensive understanding of Gilead's quarterly results.

Gilead Sciences, Inc. reported solid financial performance for the second quarter of fiscal year 2025, with total revenues reaching $7.08 billion, a 2% increase year-over-year. This growth was primarily driven by strong performance in the HIV segment, particularly from Biktarvy and Descovy sales, which saw significant increases. The company also experienced growth in Trodelvy sales within its Oncology segment. Net income attributable to Gilead surged by 21% to $1.96 billion, with diluted earnings per share rising to $1.56. This improvement was bolstered by higher product sales and a favorable swing in unrealized gains on equity securities compared to the prior year. However, the company did incur a $190 million impairment charge related to its bulevirtide IPR&D intangible asset due to increased market competition. Despite this, Gilead's robust product sales, particularly in HIV, and a more favorable equity investment performance contributed to a strong quarter.

Gilead Sciences, Inc. (GILD) has filed a Current Report on Form 8-K detailing significant amendments to its corporate bylaws, effective July 30, 2025. The primary changes focus on enhancing the procedural and disclosure requirements for stockholder nominations of directors and the submission of proposals at stockholder meetings. These amendments aim to increase transparency and clarity around shareholder actions, particularly concerning advance notice provisions. Investors should note the strengthened background information requirements for proposing stockholders and nominees, as well as explicit compliance mandates with SEC regulations like the universal proxy rules. Furthermore, the Amended and Restated Bylaws address the exclusive use of the company's white proxy card, update provisions related to meeting adjournments and stockholder lists to align with Delaware law, and clarify director election majority vote provisions and board vacancy filling. The changes also include provisions for emergency conditions and other administrative updates. While these amendments do not immediately impact financial performance, they are crucial for understanding corporate governance and the mechanics of shareholder engagement moving forward.

Gilead Sciences, Inc. (GILD) filed an 8-K on May 7, 2025, reporting the results of its 2025 annual meeting of stockholders held on May 6, 2025. The meeting saw strong participation, with over 1.12 billion shares represented, ensuring a quorum. Key outcomes include the election of all nine director nominees, who will serve for the upcoming year. Stockholders also overwhelmingly ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2025. Furthermore, shareholders provided advisory approval for the compensation of the Company's Named Executive Officers. However, several stockholder proposals did not receive sufficient support. These included proposals requesting the CEO pay ratio factor be included in executive compensation programs, the adoption of an independent Board Chair policy, a comprehensive human rights policy, and a report on the risks of DEI practices for contractors. The overwhelming rejection of these proposals suggests shareholder alignment with the current board and management's approach to these governance and policy matters.

Gilead Sciences, Inc. reported a net income of $1.3 billion for the first quarter of 2025, a significant recovery from the $4.2 billion net loss in the prior year's quarter. This turnaround was largely driven by the absence of a substantial $3.9 billion acquired in-process R&D expense related to the CymaBay acquisition and a $2.4 billion IPR&D impairment charge recorded in Q1 2024, both of which did not recur. Total revenues remained stable at $6.7 billion, with a slight decrease of 1% in product sales, which was mitigated by an increase in royalty, contract, and other revenues. Key drivers of revenue performance included a 6% increase in HIV product sales, primarily from Biktarvy, and a 3% rise in Liver Disease products, boosted by the launch of Livdelzi. Conversely, Veklury sales saw a sharp decline of 45% due to lower COVID-19 related hospitalizations. Oncology sales experienced a slight decrease. The company continues to focus on its strategic priorities, including investing in its R&D pipeline and business development, while demonstrating a strong liquidity position with $7.9 billion in cash and cash equivalents as of March 31, 2025.

Gilead Sciences, Inc. (GILD) has filed an 8-K to report its financial results for the first quarter ended March 31, 2025. The company released its earnings on April 24, 2025, and this filing serves as a notification and includes the official press release detailing these results. Investors should refer to Exhibit 99.1 for the complete financial performance information. The press release provides both GAAP and non-GAAP financial measures. Gilead's management believes the non-GAAP figures offer valuable insights into operational performance and are used for internal planning, budgeting, and financial operations. A reconciliation between GAAP and non-GAAP results is available within the press release, allowing investors to fully understand the presented financial data.

Gilead Sciences, Inc. (GILD) announced a significant change in its senior accounting leadership via an 8-K filing on March 12, 2025. Sandra Patterson, the Senior Vice President, Corporate Controller and Chief Accounting Officer, and principal accounting officer, has departed from the company. This leadership transition necessitates a search for a permanent successor. In the interim, the Board of Directors has appointed Diane E. Wilfong to serve as the interim Corporate Controller and Chief Accounting Officer, and interim principal accounting officer. Ms. Wilfong brings a wealth of experience to this role, having previously held the position of Corporate Controller and Chief Accounting Officer at Gilead from 2016 to 2023, and prior experience at Computer Sciences Corporation, Caesars Entertainment, and Eastman Kodak. Her reappointment suggests a focus on stability and experienced oversight during this transition period.

Gilead Sciences, Inc. (GILD) reported total revenues of $28.8 billion for the year ended December 31, 2024, representing a 6% increase compared to the previous year. This growth was primarily driven by strong performance in its HIV, Oncology, and Liver Disease segments. However, net income attributable to Gilead saw a significant decrease of 92% to $480 million, largely due to substantial impairment charges related to Trodelvy's non-small cell lung cancer (NSCLC) program ($4.2 billion) and higher expenses from the CymaBay acquisition ($3.8 billion). The company is strategically focused on maximizing revenue growth, capitalizing on long-acting HIV therapies, and expanding its oncology portfolio. Key product highlights include continued demand for Biktarvy and expansion of Livdelzi's indication. Looking ahead to 2025, Gilead anticipates continued demand growth for its products, but expects this to be tempered by the effects of the Inflation Reduction Act, a decline in Veklury sales due to reduced COVID-19 hospitalizations, and the impact of a strengthening U.S. dollar. The company maintains a robust R&D pipeline and continues to pursue strategic collaborations and business development opportunities.

Gilead Sciences, Inc. (GILD) has filed an 8-K report on February 11, 2025, to announce its financial results for the fourth quarter and full year ended December 31, 2024. The report primarily directs investors to an accompanying press release (Exhibit 99.1) which contains the detailed financial outcomes and management's commentary. Investors should note that Gilead provides both GAAP and non-GAAP financial measures, with management believing the non-GAAP figures offer valuable insights into operational performance for internal planning and budgeting purposes. While specific figures are not detailed within the 8-K itself, the filing indicates that the press release includes a comprehensive reconciliation between GAAP and non-GAAP financial information. This reconciliation is crucial for investors seeking to understand the nuances of Gilead's financial reporting. The information provided in this 8-K, including the press release, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, meaning it does not carry the same liability as a formally filed document.

Gilead Sciences, Inc. (GILD) has filed a Current Report Amendment (8-K/A) to disclose a key executive transition. Merdad V. Parsey, M.D., Ph.D., the current Chief Medical Officer (CMO), will be departing the company after a transition period. He will serve as a Senior Advisor through the first quarter of 2025 before his employment terminates without cause. Dietmar Berger, M.D., Ph.D., has been appointed to succeed Dr. Parsey as the new CMO, effective January 2, 2025. This leadership change in a critical role such as Chief Medical Officer is a significant development for investors to monitor, as it could impact the company's clinical development pipeline and strategic direction. The filing also includes a press release dated December 12, 2024, as an exhibit.

Gilead Sciences, Inc. (GILD) has filed an 8-K report detailing a significant financing transaction. On November 20, 2024, the company entered into a Tenth Supplemental Indenture to issue approximately $3.5 billion in aggregate principal amount of senior notes across four different series: 4.80% Senior Notes due 2029 ($750 million), 5.10% Senior Notes due 2035 ($1 billion), 5.50% Senior Notes due 2054 ($1 billion), and 5.60% Senior Notes due 2064 ($750 million). These notes were issued under the company's effective shelf registration statement and the proceeds are intended for general corporate purposes, which may include the repayment of existing indebtedness. The transaction represents a strategic move to bolster Gilead's liquidity and potentially optimize its capital structure. Investors should note the various interest rates and maturity dates associated with these new debt obligations, as well as the covenants and redemption provisions outlined in the supplemental indenture.

Gilead Sciences, Inc. reported strong revenue growth in the third quarter of 2024, with total revenues reaching $7.5 billion, a 7% increase year-over-year, driven primarily by robust performance in its HIV segment. This growth was partially offset by significant non-cash charges, including an $1.8 billion impairment related to the Trodelvy NSCLC IPR&D asset and higher acquired IPR&D expenses, which resulted in a net loss of $1.3 billion for the nine-month period. Despite the net loss, the company demonstrated positive operating cash flow, highlighting the underlying strength of its commercial operations and the ongoing demand for its key products. The company continues to strategically invest in its pipeline and expand its portfolio through acquisitions and collaborations. Notable developments include the FDA's accelerated approval of Livdelzi for primary biliary cholangitis and positive Phase 3 data for lenacapavir in HIV prevention, positioning Gilead for future growth. However, the company faces ongoing legal challenges and potential patent expirations, which remain key areas for investor attention.

Gilead Sciences, Inc. (GILD) filed an 8-K on November 6, 2024, to report its financial results for the quarter ended September 30, 2024. The filing primarily consists of a press release announcing these results, which provides both GAAP and non-GAAP financial information. Investors should refer to the press release, filed as Exhibit 99.1, for detailed financial performance data, including comparisons and reconciliations between GAAP and non-GAAP metrics. The company emphasizes that its non-GAAP financial information is provided as a supplementary measure, useful for understanding operational performance and for internal management purposes. While management believes these non-GAAP measures offer valuable insights, they are not prepared under comprehensive accounting rules and may differ from how other companies define and calculate similar metrics. Investors are advised to consider this non-GAAP information alongside Gilead's official GAAP financial statements for a complete understanding.

Gilead Sciences, Inc. (GILD) has filed an 8-K report on August 8, 2024, to announce its financial results for the quarter ended June 30, 2024. The report primarily references an attached press release (Exhibit 99.1) which contains detailed financial information. Investors should note that Gilead presents its financial data on both a U.S. GAAP and a non-GAAP basis. Management believes the non-GAAP figures provide additional useful insights for investors, complementing the official GAAP statements, and are used internally for operational and strategic planning. A reconciliation of GAAP to non-GAAP measures is available within the press release. While the specific financial figures are detailed within the referenced press release and not fully reproduced in the 8-K text itself, the filing serves as the official notification to the market regarding these results. Investors are encouraged to review Exhibit 99.1 for comprehensive details on revenue, earnings, and other key performance indicators for the second quarter of 2024, as well as management's commentary and outlook.

Gilead Sciences, Inc. (GILD) reported $6.95 billion in total revenues for the second quarter of 2024, a 5% increase compared to the same period last year. This growth was primarily driven by strong performance in HIV, Oncology, and Liver Disease segments. Diluted earnings per share (EPS) for the quarter were $1.29, a significant increase from $0.83 in Q2 2023, reflecting improved revenues and lower operating expenses. Despite a strong Q2 performance, the six-month period ending June 30, 2024, showed a net loss of $2.56 billion. This was largely attributable to a significant acquired in-process R&D charge of $3.9 billion related to the CymaBay acquisition and a $2.4 billion impairment charge on IPR&D assets for Trodelvy's NSCLC indication. The company also reported a decrease in cash and cash equivalents, primarily due to the CymaBay acquisition and dividend payments. Gilead's balance sheet remains robust, but investors should monitor the impact of significant R&D charges and ongoing litigation.

Gilead Sciences, Inc. (GILD) announced on July 17, 2024, that its Chief Medical Officer, Merdad V. Parsey, M.D., Ph.D., will be departing the company. Dr. Parsey will continue in his role during the search for a successor and to assist with the transition of his responsibilities, which is expected to extend through the first quarter of 2025 or an otherwise mutually agreed-upon date. This executive departure, while not indicating any immediate financial impact or strategic shift in the filing itself, is a significant event for a company heavily reliant on its clinical development and medical affairs leadership. Investors will be looking for clarity on the succession plan and the continuity of Gilead's research and development pipeline during this transition period.

Gilead Sciences, Inc. (GILD) filed an 8-K on May 9, 2024, detailing the outcomes of its 2024 Annual Meeting of Stockholders held on May 8, 2024. The primary focus of the filing is the approval of amendments to the company's Restated Certificate of Incorporation, specifically to align with new Delaware laws on officer exculpation. This change, adopted by the Board in February and approved by stockholders, aims to further protect officers from personal liability for certain breaches of fiduciary duty, a common corporate governance update in Delaware. Beyond governance, the meeting saw the election of nine directors to the Board, all of whom received strong support from shareholders. Key proposals included the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024, and an advisory vote on executive compensation, both of which were approved. Importantly, several stockholder proposals, including those related to employee board representation, reporting on risks associated with state policies on abortion, and enhanced executive stock retention, were not approved by the majority of shareholders.

Gilead Sciences, Inc. reported a net loss of $4.17 billion for the first quarter of 2024, a significant decrease from a net income of $1.01 billion in the prior year period. This loss was largely attributed to a substantial acquired in-process research and development (IPR&D) charge of $3.9 billion related to the acquisition of CymaBay Therapeutics and a $2.4 billion impairment charge for certain IPR&D assets connected to Trodelvy. Despite the net loss, total revenues saw a 5% increase year-over-year, reaching $6.69 billion. This growth was driven by strong performance in HIV and Oncology segments, with notable increases in Biktarvy and Trodelvy sales. However, Veklury sales experienced a decline, reflecting decreased COVID-19 related hospitalizations. Financial activities during the quarter included significant investments in acquisitions, notably the CymaBay purchase, and ongoing share repurchases and dividend payments, contributing to a decrease in cash and cash equivalents.

Gilead Sciences, Inc. (GILD) filed an 8-K on April 25, 2024, to report its financial results for the first quarter ended March 31, 2024. The report primarily directs investors to a press release (Exhibit 99.1) for detailed financial performance, including both GAAP and non-GAAP measures. Management emphasizes the utility of non-GAAP figures for internal operational and financial planning, suggesting these provide valuable insights alongside the official GAAP statements for investors. Investors should refer to the press release for specific figures regarding revenue, earnings per share, and other key financial metrics for the quarter. The filing itself is procedural, confirming the release of these results and highlighting the availability of supplementary non-GAAP information. It's important for investors to review the provided reconciliation tables to understand the differences between GAAP and non-GAAP reporting.

Gilead Sciences, Inc. announced the successful completion of its acquisition of CymaBay Therapeutics, Inc. on March 22, 2024. The acquisition was executed through a tender offer that commenced on February 23, 2024, with Gilead offering $32.50 per share in cash. The tender offer successfully secured approximately 77.3% of CymaBay's outstanding shares, exceeding the minimum tender condition. Following the tender offer, Gilead proceeded with a merger under Delaware law, converting all remaining eligible shares not already acquired in the tender offer into the right to receive the same $32.50 per share in cash. The total aggregate consideration paid by Gilead for this acquisition amounts to approximately $4.3 billion. This strategic move is expected to bolster Gilead's pipeline and therapeutic offerings, particularly in areas where CymaBay has a presence.

Gilead Sciences, Inc. (GILD) filed an 8-K report on March 14, 2024, to announce the upcoming retirement of a key board member. Kevin E. Lofton, a member of the Board of Directors, has notified the company of his decision to retire, which will be effective at the conclusion of his term at the company's next annual meeting of stockholders on May 8, 2024. This transition appears to be planned and voluntary, as the filing explicitly states that Mr. Lofton's decision was not due to any disagreements with the Board or management.

Gilead Sciences, Inc. reported total revenues of $27.1 billion for the fiscal year 2023, a slight decrease of 1% compared to 2022. This was primarily driven by a significant drop in Veklury (remdesivir) sales due to lower COVID-19 related hospitalizations, which was largely offset by robust growth in HIV and Oncology product sales. Net income attributable to Gilead increased by 23% to $5.7 billion, with diluted earnings per share rising 24% to $4.50. This improvement was largely due to lower impairment charges related to in-process research and development, reduced net unrealized losses on equity investments, and increased interest income. The company continues to strategically invest in its R&D pipeline through acquisitions and collaborations, particularly in oncology and inflammation. Key developments include expanded collaborations and the acquisition of smaller biotech firms to bolster its pipeline. Patent expirations for some key products are on the horizon, with major HIV products like Descovy and Vemlidy having U.S. patent expirations in 2031, and Biktarvy in 2033. The company also faces ongoing litigation, including challenges related to its HIV products and the sale of its PrEP medications, though recent legal outcomes have been favorable in some instances. Gilead maintains a strong liquidity position and continues to return capital to shareholders through dividends and share repurchases.

Gilead Sciences, Inc. (GILD) announced a significant development with the entry into a definitive Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. The acquisition will be executed through a tender offer at $32.50 per share in cash, valuing CymaBay at a total transaction value not explicitly stated in this filing but implied by the per-share offer. This strategic move aims to bolster Gilead's pipeline, particularly in areas with unmet medical needs. This transaction represents a key growth initiative for Gilead, signaling a commitment to expanding its therapeutic portfolio through targeted acquisitions. Investors should monitor the progress of the tender offer, which is subject to customary closing conditions, including regulatory approvals and a minimum tender of over 50% of CymaBay's outstanding shares. The deal includes a termination fee of $151.6 million under specific circumstances, such as CymaBay accepting a superior offer.

Gilead Sciences, Inc. (GILD) filed an 8-K on February 6, 2024, announcing its financial results for the fourth quarter and full year ended December 31, 2023. The report primarily serves to include the press release detailing these financial outcomes, which offers insights into the company's operational performance and financial condition. Investors should refer to the press release (Exhibit 99.1) for specific figures and management's commentary on the results. The company highlighted that it presents financial information on both a GAAP and a non-GAAP basis. Gilead emphasizes that non-GAAP measures are provided as a supplementary view, believed to be useful for investors, and are used internally for operational and financial planning. A reconciliation between GAAP and non-GAAP figures is available within the press release, which is crucial for a comprehensive understanding of the reported financial health and operational efficiency.

Gilead Sciences, Inc. (GILD) announced a change to its Board of Directors in an 8-K filing on February 2, 2024. The company increased the size of its board from nine to ten directors and elected Ted W. Love, M.D., as a new director, effective immediately after the Board meeting on February 1, 2024. Dr. Love will also serve on the Audit Committee, subject to re-election by stockholders at the upcoming 2024 Annual Meeting. This appointment is a notable governance update for investors, indicating a potential addition of valuable expertise to the Board's oversight functions, particularly within the Audit Committee. Dr. Love's compensation will align with the company's standard non-employee director compensation programs, including equity grants under the 2022 Equity Incentive Plan. The filing also includes a press release announcing this appointment as an exhibit.

Gilead Sciences, Inc. reported steady revenues for the third quarter and the first nine months of 2023, with total revenues reaching $7.05 billion and $20.0 billion, respectively, showing a slight increase of 1% year-over-year for the nine-month period. Net income attributable to Gilead saw significant growth, up 22% to $2.18 billion for the quarter and 44% to $4.24 billion for the nine months, driven by increased product sales in Oncology and HIV, along with a favorable year-over-year comparison due to the absence of a large IPR&D impairment charge recognized in the prior year. Product sales within the HIV segment demonstrated robust growth, particularly Biktarvy, contributing to a 4% increase in HIV product sales for the quarter. The Oncology segment also performed strongly, with significant year-over-year increases in both Cell Therapy (Yescarta and Tecartus) and Trodelvy sales, reflecting continued demand and successful market penetration. However, sales of Veklury, the company's COVID-19 treatment, declined substantially due to decreased COVID-19 hospitalizations and the availability of alternative treatments. The company also addressed a significant legal settlement related to HIV antitrust litigation, paying $525 million in the second half of the year, which impacted operating expenses.

Gilead Sciences, Inc. (GILD) filed an 8-K on November 7, 2023, to announce its third-quarter financial results for the period ending September 30, 2023. The filing primarily directs investors to a press release (Exhibit 99.1) containing detailed financial performance data, including both GAAP and non-GAAP measures. Management believes that the non-GAAP information provides useful insights for investors as it is used internally for operational and financial planning. Investors are encouraged to review the press release and the accompanying reconciliation of GAAP to non-GAAP financial measures for a comprehensive understanding of the company's performance. The press release itself will contain the specific figures regarding revenue, profitability, and any forward-looking guidance. While this 8-K filing does not provide the direct financial numbers, it serves as the official notification and access point to the third-quarter earnings report, allowing investors to assess the company's recent performance and outlook.

Gilead Sciences, Inc. (GILD) has filed an 8-K report detailing the entry into a material definitive agreement concerning the issuance of new senior notes. Specifically, on September 14, 2023, the company, along with Computershare Trust Company, National Association as trustee, executed a Ninth Supplemental Indenture. This indenture allows for the issuance of $1 billion in 5.250% Senior Notes due 2033 and $1 billion in 5.550% Senior Notes due 2053, totaling $2 billion in aggregate principal amount. These notes were sold through a public offering under an existing registration statement. The proceeds from this offering are intended for general corporate purposes. The filing also includes details on the underwriting agreement with Barclays Capital Inc. and Citibank Global Markets Inc., acting as representatives for the underwriters. The supplemental indenture outlines various covenants and restrictions, including limitations on secured indebtedness, sale and leaseback transactions, and provisions for debt repurchases upon a change of control. The company retains the option to redeem these notes under specified conditions.

Gilead Sciences, Inc. (GILD) filed an 8-K on August 16, 2023, primarily to disclose preliminary results from the EVOKE-02 study concerning the combination of Sacituzumab Govitecan and Pembrolizumab in first-line metastatic non-small cell lung cancer (NSCLC). This information was inadvertently posted by the International Association for the Study of Lung Cancer (IASLC) on their conference website ahead of Gilead's planned disclosure. The preliminary results, presented in Exhibit 99.1, offer an early look at the efficacy and safety of this combination therapy for a significant patient population. While the company emphasizes that this disclosure was not authorized and the data is preliminary, it provides investors with crucial early insights into a potential new treatment option in the competitive oncology market. Investors should note that this is not an official earnings release or a comprehensive update but a disclosure of study data shared publicly earlier than anticipated.

Gilead Sciences, Inc. (GILD) reported revenues of $6.60 billion for the third quarter of 2023, a 5% increase year-over-year, driven by growth in HIV and Oncology segments. However, net income attributable to Gilead saw a significant decrease of 9% to $1.045 billion, or $0.83 per diluted share. This decline was primarily influenced by a $525 million litigation accrual for settlements related to HIV antitrust litigation, coupled with higher operating costs and tax expenses. For the first six months of 2023, revenues grew 1% to $12.95 billion, while net income more than doubled to $2.06 billion, largely due to the absence of a significant $2.7 billion IPR&D impairment charge recognized in the prior year's comparable period. The company's strategic focus continues to be on advancing innovative medicines for life-threatening diseases. Acquisitions in the oncology space, such as XinThera and Tmunity, alongside collaborations like Arcellx, highlight Gilead's commitment to expanding its pipeline. Despite a challenging legal environment and increased R&D spending, Gilead's core HIV franchise remains robust, and its cell therapy and oncology products are demonstrating strong growth.

Gilead Sciences, Inc. (GILD) announced its financial results for the quarter ended June 30, 2023, via a press release filed on August 3, 2023. The report primarily serves to furnish this press release, which contains detailed financial performance information, including both GAAP and non-GAAP measures. Investors should refer to the press release (Exhibit 99.1) for a comprehensive understanding of the company's operational performance and financial condition during the second quarter of 2023. The company utilizes non-GAAP financial measures alongside GAAP results to provide a more insightful view of its operations, budgeting, and financial planning. While these non-GAAP metrics are considered useful by management, they are not prepared under comprehensive accounting rules and should be used as supplementary information to the official GAAP financial statements. A reconciliation of GAAP to non-GAAP figures is available within the press release itself, allowing investors to compare these different reporting bases.

Gilead Sciences, Inc. (GILD) filed an 8-K on May 4, 2023, reporting on the outcomes of its Annual Meeting of Stockholders held on May 3, 2023. The primary focus for investors is the overwhelming approval of amendments to the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan. This indicates strong stockholder support for employee equity participation and potentially the company's strategy to retain and incentivize its workforce through stock ownership. Additionally, the filing confirms the election of nine directors and the ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2023. The meeting also included advisory votes on executive compensation, with stockholders approving the compensation of Named Executive Officers and supporting annual advisory votes on executive compensation going forward. Notably, several stockholder proposals, including those related to director nominations, special meeting rights for different share classes, and the impact of patent exclusivities on product access, did not receive majority support from stockholders. This suggests that management's recommendations on these matters were largely followed.

Gilead Sciences, Inc. reported total revenues of $6.35 billion for the first quarter of 2023, a 4% decrease year-over-year, primarily due to lower sales of Veklury (remdesivir). However, the company saw strong growth in its oncology portfolio, with significant increases in Cell Therapy (up 64%) and Trodelvy (up 52%), driven by expanded adoption and new indications. HIV product sales also increased by 13%, indicating continued strength in this core franchise, bolstered by Biktarvy and Descovy for PrEP. Net income attributable to Gilead significantly improved to $1.01 billion, or $0.80 per diluted share, compared to $19 million, or $0.02 per diluted share, in the prior year. This substantial increase was largely driven by the absence of a $2.7 billion in-process research and development impairment charge recorded in Q1 2022. Gilead also made strategic investments, including the acquisition of Tmunity Therapeutics and a collaboration with Arcellx, signaling a continued focus on expanding its oncology pipeline. The company maintained a healthy operating cash flow of $1.74 billion.

Gilead Sciences, Inc. (GILD) filed an 8-K on April 27, 2023, to report its financial results for the quarter ended March 31, 2023. The filing primarily consists of a press release detailing these results. Investors should note that Gilead presents both GAAP and non-GAAP financial information, and the company believes the non-GAAP measures offer useful insights for understanding operational performance. The press release, filed as Exhibit 99.1, contains the detailed financial tables and reconciliations between GAAP and non-GAAP figures. While this 8-K itself does not contain the specific financial numbers, it serves as the official notification and filing vehicle for the quarterly earnings announcement. Investors are directed to the attached press release for the comprehensive breakdown of Gilead's financial condition and results of operations for the first quarter of 2023.

Gilead Sciences, Inc. (GILD) reported relatively flat total revenues of $27.3 billion for the fiscal year ended December 31, 2022, compared to the prior year. This stability was driven by growth in key areas like HIV, cell therapy, and Trodelvy, which offset a significant decline in Veklury (remdesivir) sales due to lower COVID-19 hospitalization rates. However, net income saw a substantial decrease of 26% to $4.6 billion, largely impacted by a $2.7 billion impairment charge related to Trodelvy's in-process R&D, higher R&D expenses, and a one-time charge in the prior year for a bictegravir litigation settlement that did not recur. Despite the net income decline, the company continues to invest in its pipeline through strategic acquisitions and collaborations, and returned value to shareholders through dividends and share repurchases.

Gilead Sciences, Inc. (GILD) has filed an 8-K report on February 6, 2023, announcing an amendment to its corporate bylaws. The primary change involves a reduction in the ownership threshold required for stockholders to call a special meeting. This threshold has been lowered from 20% to 15% of the company's outstanding common stock. This amendment is significant for investors as it potentially empowers a broader group of shareholders to initiate special meetings, thereby increasing engagement and the possibility of addressing shareholder concerns or proposals more directly. While the company has not disclosed specific reasons for this change, it could signal a move towards greater shareholder responsiveness or be a proactive measure in anticipation of potential future shareholder activism.

Gilead Sciences, Inc. (GILD) has filed a Current Report (8-K) on February 2, 2023, to announce its financial results for the fourth quarter and full year ended December 31, 2022. The filing includes a press release detailing these results, which were presented on both a GAAP and non-GAAP basis. Management believes the non-GAAP information provides useful insights for investors, aiding in the understanding of the company's operational performance and financial planning. Investors should refer to the press release (Exhibit 99.1) for a comprehensive overview of Gilead's financial performance, including a reconciliation of non-GAAP measures to GAAP. The company emphasizes that non-GAAP financial information should be used to supplement, not replace, the understanding of GAAP-reported results and that definitions may vary among industry peers.

Gilead Sciences, Inc. reported total revenues of $7.04 billion for the third quarter of 2022, a 5% decrease from the prior year's $7.42 billion. This decline was primarily driven by a significant drop in Veklury sales, down 52%, as COVID-19 hospitalizations decreased. However, growth in HIV products, cell therapy, and Trodelvy partially offset this decline. Net income attributable to Gilead stockholders was $1.79 billion, or $1.42 per diluted share, compared to $2.59 billion, or $2.05 per diluted share, in the same period last year. The decrease in net income was largely due to a $389 million charge related to the acquisition of MiroBio and a substantial $2.7 billion impairment charge on acquired in-process R&D assets recognized in the second quarter related to Trodelvy. Despite these charges, Gilead continues to invest in R&D and returned capital to shareholders through share repurchases and dividends.

Gilead Sciences, Inc. (GILD) filed an 8-K on October 27, 2022, to announce its financial results for the third quarter ended September 30, 2022. The report primarily directs investors to a press release (Exhibit 99.1) for detailed financial performance, including both GAAP and non-GAAP measures. Investors should review this press release for specific figures regarding revenue, earnings, and other key financial metrics. The company emphasizes that non-GAAP financial information is provided as a supplemental measure to aid investor understanding and is used internally for operational and planning purposes. A reconciliation between GAAP and non-GAAP figures is available within the press release. While this filing itself doesn't contain the detailed financial tables, it formally notifies the market of the results and directs stakeholders to the complete unaudited financial information.

Gilead Sciences, Inc. (GILD) announced on September 12, 2022, that it has reached agreements with several generic manufacturers to resolve patent litigation concerning its key HIV and Hepatitis B medications: Descovy®, Vemlidy®, and Odefsey®. These agreements grant non-exclusive licenses in the United States for the underlying patents related to tenofovir alafenamide. This resolution is significant for investors as it clarifies the future market entry of generic versions of these important drugs. The licenses begin on October 31, 2031, for Descovy and Vemlidy, and January 31, 2032, for Odefsey, with potential earlier termination under specific conditions. This provides Gilead with a defined period of market exclusivity for these products in the US, mitigating immediate patent challenges and offering a degree of predictability for future revenue streams.

Gilead Sciences, Inc. (GILD) reported its second-quarter 2022 financial results, showing a slight increase in total revenues to $6.26 billion, up 1% year-over-year. This growth was primarily driven by strong performance in its HIV, Cell Therapy, and Trodelvy segments, which offset declines in Veklury and Hepatitis C virus (HCV) sales. However, net income attributable to Gilead decreased significantly by 25% to $1.14 billion, resulting in diluted earnings per share of $0.91. This decline was mainly due to a substantial $2.7 billion in-process research and development (IPR&D) impairment charge recorded in the first quarter related to Trodelvy, and an upfront payment for the Dragonfly collaboration. The company's balance sheet remains robust, with total assets of $62.87 billion as of June 30, 2022. While cash and cash equivalents decreased to $4.74 billion, Gilead generated positive operating cash flow of $3.64 billion for the first six months of the year. The company also continues to actively manage its capital structure, repaying debt and returning capital to shareholders through dividends and share repurchases. Gilead also announced a pending acquisition of MiroBio Ltd. for $405 million, signaling continued investment in pipeline expansion.

Gilead Sciences, Inc. (GILD) has filed an 8-K report on August 2, 2022, to announce its financial results for the second quarter ended June 30, 2022. The report primarily refers to a press release (Exhibit 99.1) which contains the detailed financial performance and operational highlights for the period. Investors should review this press release for a comprehensive understanding of the company's performance and its forward-looking statements. The company has provided financial information on both a GAAP and non-GAAP basis, with management emphasizing that the non-GAAP figures are used for internal operational and planning purposes and are intended to supplement, not replace, GAAP financial statements. A reconciliation between GAAP and non-GAAP measures is available within the press release, which is crucial for investors seeking to understand the nuances of Gilead's financial reporting and make informed investment decisions.

Gilead Sciences, Inc. (GILD) announced a planned leadership transition in its finance department. Diane Wilfong, Senior Vice President, Corporate Controller, and Chief Accounting Officer, will step down from her principal accounting officer role on March 1, 2023. Ms. Wilfong will remain with the company to ensure a smooth transition and support strategic initiatives. Sandra Patterson, currently Vice President, Assistant Controller, is appointed to succeed Ms. Wilfong as Senior Vice President, Corporate Controller, and principal accounting officer, also effective March 1, 2023. Ms. Patterson brings extensive experience within Gilead and from prior roles at prominent companies, along with relevant professional qualifications. This transition is a routine management change aimed at ensuring continuity and leveraging existing talent within the organization.

Gilead Sciences, Inc. (GILD) filed an 8-K on May 31, 2022, primarily to disclose information regarding a compensatory arrangement for Brett A. Pletcher, Executive Vice President, Corporate Affairs and General Counsel. Mr. Pletcher is retiring from his full-time role but will transition to a part-time capacity. This arrangement is designed to ensure a smooth handover of his responsibilities and to leverage his expertise in ongoing litigation matters. Investors should note that this move is focused on executive transition and continued support rather than significant operational or financial changes.